On 02-12-2019 (Monday), Shares of ImmunoGen, Inc., (NASDAQ: IMGN) displayed a change of -1.25 after which it closed the day’ session at $3.57. The volume amounted to 2276510 shares which compares with the average volume of 1.67M shares. ImmunoGen, Inc., a USA based Company, belongs to Healthcare sector and Biotechnology industry. The shares of ImmunoGen, Inc. was among the active stocks of the last trading sessions.
To clear the blur picture shareholders will need to look a little deeper. The LiveRamp Holdings, Inc. has shown a weekly performance of 10.4% and monthly performance stands at 45.56%.
The stock has shown a quarterly performance of 32.72% and a half-year performance stands at 94.09%. Analyst recommendation for this stock stands at -24.79.
The stock price moved with change of 0.6022 to its 50 Day low point and changed -0.1305 comparing to its 50 Day high point.
Looking into the profitability ratios of IMGN stock, the investor will find its ROE, ROA, ROI standing at 352.6%, -51.9% and 0%, respectively. The current relative strength index (RSI) reading is 62.48.
Target Price IMGN:
Target Price informs the investors, a stock survey at which a trader is willing to buy or sell a stock. Target pricing at which a trader projects that a buyer will buy a product. Analyst’s mean target price for the company is $4.67.
The stock price volatility remained at 9.27 in recent month and reaches at 9.48 for the week. The Average True Range (ATR) is also a measure of volatility is currently sitting at 0.26.
Simple Moving Averages IMGN:
The moving average is easy to calculate and once plotted on a chart, is a powerful visual trend-spotting tool. In theory, there is an infinite number of simple moving averages but the most common are three SMA20, SMA50 and SMA200. SMA20 is the last stop on the bus for short-term traders. Its distance from 20-days simple moving average is 6.65% and its distance from 50-days simple moving average is 23.99% while it has a distance of 30.55% from the 200-days simple moving average.
Most Important details of ImmunoGen, Inc. (EPS):
EPS in next five year years is expected to touch -7.6% while EPS growth in past 5 year was -7.6% along with sales growth of % in the last five years. EPS growth in next year is estimated to reach -23.2% while EPS growth estimate for this year is set at -23.2%.